Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 16/20 | 0.68 |
| ▸ | TNNI3K | Q59H18 | 16/20 | 0.68 |
| ▸ | BRAF | P15056 | 15/20 | 0.68 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | CDK7 | P50613 | 1/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4936682 | 0.84 | KDR (0.64) | KDRMAPK14TNNI3KBRAFFLT1 | |
| SCHEMBL3180722 | 0.82 | KDR (1.00) | KDRMAPK14TNNI3KBRAFFLT1 | |
| SCHEMBL4939906 | 0.79 | KDR (0.71) | KDRMAPK14TNNI3KBRAFFLT1 | |
| SCHEMBL4936701 | 0.79 | KDR (0.73) | KDRMAPK14TNNI3KBRAFFLT1 | |
| SCHEMBL4936683 | 0.76 | KDR (0.65) | KDRMAPK14TNNI3KBRAF | |
| SCHEMBL4766035 | 0.75 | KDR (0.64) | KDRMAPK14TNNI3KBRAF | |
| SCHEMBL22528714 | 0.75 | KDR (0.70) | KDRMAPK14TNNI3KBRAFFLT1 | |
| SCHEMBL1896470 | 0.74 | KDR (0.73) | KDRMAPK14TNNI3KBRAFCDK8 | |
| SCHEMBL2762594 | 0.74 | KDR (0.76) | KDRMAPK14TNNI3KBRAFCDK8 | |
| SCHEMBL4932660 | 0.73 | KDR (0.66) | KDRMAPK14TNNI3KBRAFFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | BOLD GUIDO | 2008-12-18 | — | — | US | claimed |
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | BOLD GUIDO | 2008-12-18 | — | — | US | disclosed |
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | BOLD GUIDO | 2008-12-18 | — | — | US | disclosed |
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | BOLD GUIDO | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | RET, PRKDC, PRKACA | KDR 1309/4885MAPK14 343/4885TNNI3K 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.